Q-TWiST analysis of pembrolizumab combined with chemotherapy as first-line treatment of metastatic triple-negative breast cancer that expresses PD-L1
Huang M, O'Shaughnessy J, Haiderali A, Pan W, Hu P, Chaudhuri M, Le Bailly De Tilleghem C, Cappoen N, Fasching P (2022)
Publication Type: Journal article
Publication year: 2022
Journal
Book Volume: 177
Pages Range: 45-52
DOI: 10.1016/j.ejca.2022.09.029
Abstract
Objective: In the KEYNOTE-355 (KN355) trial, pembrolizumab in combination with chemotherapy demonstrated superior efficacy and manageable safety compared with chemotherapy alone in patients with previously untreated locally recurrent inoperable and metastatic triple-negative breast cancer (mTNBC) with PD-L1 positive (Combined Positive Score [CPS]≥ 10) tumours. This study aimed to evaluate the clinical benefits and risks of pembrolizumab measured by quality-adjusted survival in the trial population. Methods: The study used data from the final analysis of KN355. The Quality-adjusted Time Without Symptoms of disease progression or Toxicity of treatment (Q-TWiST) analysis was used to compare treatments of pembrolizumab plus chemotherapy versus chemotherapy alone. Patients’ survival time was partitioned into three health states — toxicity before disease progression (TOX), time without symptoms or toxicity before disease progression (TWiST), and relapse (REL). Utilities for these health states were estimated using EuroQol-5 Dimensions, 3 Levels (EQ-5D-3L) data collected in KN355. Q-TWiST was derived as the utility-weighted sum of the mean health state durations. Results: Patients randomised to pembrolizumab plus chemotherapy had 3.7 months greater Q-TWiST (relative gain of 18%; P = 0.003) compared to those randomised to chemotherapy at the median follow-up of 44 months, and 4.3 months greater Q-TWiST (relative gain of 20%; P = 0.004) at the maximum follow-up of 52 months. The Q-TWiST gain increased with longer follow-up time. Conclusions: Pembrolizumab plus chemotherapy was associated with statistically significant and clinically important improvement in Q-TWiST compared to chemotherapy in previously untreated PD-L1–positive mTNBC.
Authors with CRIS profile
Involved external institutions
Complete Health Economics Outcomes and Research Solutions (CHEORS)
United States (USA) (US)
Merck & Co., Inc. / Merck Sharp & Dohme Corp (MSD)
United States (USA) (US)
Baylor University Medical Center
United States (USA) (US)
United States (USA) (US)
Merck & Co., Inc. / Merck Sharp & Dohme Corp (MSD)
United States (USA) (US)
Baylor University Medical Center
United States (USA) (US)
How to cite
APA:
Huang, M., O'Shaughnessy, J., Haiderali, A., Pan, W., Hu, P., Chaudhuri, M.,... Fasching, P. (2022). Q-TWiST analysis of pembrolizumab combined with chemotherapy as first-line treatment of metastatic triple-negative breast cancer that expresses PD-L1. European Journal of Cancer, 177, 45-52. https://doi.org/10.1016/j.ejca.2022.09.029
MLA:
Huang, Min, et al. "Q-TWiST analysis of pembrolizumab combined with chemotherapy as first-line treatment of metastatic triple-negative breast cancer that expresses PD-L1." European Journal of Cancer 177 (2022): 45-52.
BibTeX: Download